Part of the results of DR70-vet were presented in the American College of Internal Medicine and Veterinary Medicine (ACVIM) in June this year. This study was jointly developed by our company and Professor Chenqi Lin from the Department of Veterinary Medicine of National Taiwan University, which confirmed that DR70-vet can be used as a biomarker for the identification of malignant tumors in dogs and the monitoring of the course of the disease. Sensitivity and specificity reach more than 80%!
Media Information
Business Times
Huayu Pharmaceutical Pet Cancer Screening Sharps Medical Annual Meeting Show Results
2022 Livelihood Investment First Stop – GENET:
Pet cancer screening may change post-treatment tracking, Uni Pharma (6621) innovative research has attracted international attention
http://www.genetinfo.com/investment/featured/item/60648.html
Eastern Sen Financial News
Xingji: Huayu Pharmaceutical Pet Cancer Screening is Expected to Change the Criteria for Post-Treatment Cancer Tracking, and the Start-Up Research Has Attracted International Attention
https://fnc.ebc.net.tw/fncnews/else/152300
Financial News
Huayu Pharmaceutical Pet Cancer Screening is Expected to Change Post-Treatment Tracking Guidelines – Innovative Research Receives International Attention
